{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:23:36Z","timestamp":1783441416483,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vhri.2025.101567","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:41:56Z","timestamp":1766767316000},"page":"101567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Utility Analysis of Adjuvant Osimertinib in Resected Epidermal-Growth-Factor-Receptor-Mutated Early-Stage Non-Small Cell Lung Cancer"],"prefix":"10.1016","volume":"54","author":[{"given":"Supitchaya","family":"Changsatja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayanis","family":"Kositamongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucksamon","family":"Thamlikitkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pochamana","family":"Phisalprapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Touchanun","family":"Komonpaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vhri.2025.101567_bib1","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jtho.2020.04.024","article-title":"Lung cancer in Thailand","volume":"15","author":"Reungwetwattana","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101567_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12885-024-11934-2","article-title":"Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer","volume":"24","author":"Thamrongjirapat","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.vhri.2025.101567_bib3","first-page":"643","article-title":"EGFR mutation-positive lung cancer in real-world treatment outcomes: a multicenter study from Thailand","volume":"7","author":"Sukauichai","year":"2022","journal-title":"Asian Pac J Cancer Care"},{"issue":"10","key":"10.1016\/j.vhri.2025.101567_bib4","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non\u2013small-cell lung cancer: updated results from the Phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2025.101567_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vhri.2025.101567_bib6","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vhri.2025.101567_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.vhri.2025.101567_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/oncolo\/oyac021","article-title":"Modeling the cost-effectiveness of adjuvant osimertinib for patients with resected EGFR-mutant non-small cell lung cancer","volume":"27","author":"Lemmon","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.vhri.2025.101567_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1743-7563.2011.01463.x","article-title":"Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer","volume":"7","author":"Thongprasert","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2025.101567_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s41669-023-00396-0","article-title":"Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer","volume":"7","author":"Verhoek","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.vhri.2025.101567_bib12","first-page":"67","article-title":"Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non\u2013small cell lung cancer and mutated EGFR","volume":"32","author":"Vila P\u00e9rez","year":"2023","journal-title":"Support Care Cancer"},{"issue":"23","key":"10.1016\/j.vhri.2025.101567_bib13","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1002\/cam4.4798","article-title":"Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China","volume":"11","author":"Zhou","year":"2022","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.vhri.2025.101567_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101567_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vhri.2025.101567_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vhri.2025.101567_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.vhri.2025.101567_bib21","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum\u2013pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.vhri.2025.101567_bib22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non\u2013small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vhri.2025.101567_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vhri.2014.01.001","article-title":"Cost-utility analysis of erythropoietin for anemia treatment in Thai end-stage renal disease patients with hemodialysis","volume":"3","author":"Thaweethamcharoen","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2025.101567_bib27","author":"Riewpaiboon"},{"key":"10.1016\/j.vhri.2025.101567_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vhri.2013.12.001","article-title":"Epidermal growth factor receptor mutation testing in Thailand: a cost-utility analysis","volume":"3","author":"Permsuwan","year":"2014","journal-title":"Value Health Reg Issues"},{"issue":"4","key":"10.1016\/j.vhri.2025.101567_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.29090\/psa.2020.04.019.0055","article-title":"Economic burden of pneumonia, sepsis and meningitis among children aged up to 5 years old at a tertiary care hospital in Thailand: an input for economic evaluation of vaccination","volume":"47","author":"Riewpaiboon","year":"2020","journal-title":"Pharm Sci Asia"},{"key":"10.1016\/j.vhri.2025.101567_bib30","author":"O\u2019Neill"},{"issue":"10","key":"10.1016\/j.vhri.2025.101567_bib31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/thx.2010.136390","article-title":"Health-related quality of life in patients surviving non-small cell lung cancer","volume":"65","author":"Grutters","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.vhri.2025.101567_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.lungcan.2018.04.003","article-title":"Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand","volume":"120","author":"Limwattananon","year":"2018","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.vhri.2025.101567_bib33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/14737167.2022.2123796","article-title":"A systematic review of health state utility values in Thai cancer patients","volume":"22","author":"Kangwanrattanakul","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:36:41Z","timestamp":1783438601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925004935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S2212109925004935"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101567","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility Analysis of Adjuvant Osimertinib in Resected Epidermal-Growth-Factor-Receptor-Mutated Early-Stage Non-Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101567"}}